Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Turnover of API division of ISLL stood at Rs 856.58 crore
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Subscribe To Our Newsletter & Stay Updated
